High DNA content and prognosis in lymph node positive breast cancer. A case control study by the university of Leiden and ECOG

SummaryTo investigate whether breast cancer cells with unusually high nuclear DNA content are associated with an adverse outcome, Eastern Cooperative Oncology Group investigators selected breast cancer trial patients who suffered an early death (ED) within two years after diagnosis to compare with other trial patients who had a survival of at least 7.5 years. Paraffin blocks of primary breast cancers were obtained from 93 evaluable patients who had been enrolled in two surgical adjuvant trials for lymph node positive (LN +) disease (T1-3N1M0). Single cell monolayer preparations from these blocks were stained with acriflavine-Feulgen and analyzed by image analysis for DNA content with the automated Leiden Television Analysis System (LEYTAS). Standard prognostic variables (estrogen receptor (ER) status, number of lymph nodes with metastases, and size of the cancer) were compared with three DNA content characteristics: DNA ploidy status, number of nuclei with > 5C DNA content, and percent of nuclei with > 5 C. Estimates of the odds ratio in multivariate comparisons showed that ER negativity was associated with ED (p = 0.0005) and an odds ratio estimate using negative/positive of 4.87. The number of positive lymph nodes associated with ED had a p-value of 0.0005 and an odds ratio estimate of 4.63 when comparing the > 3 nodes group to the 1–3 nodes group. In contrast, the strongest association for any of the DNA content characteristics with ED had a p-value of 0.017 and an odds ratio estimate of 2.76. This power of association disappeared when stratified on ER status. Therefore, the presence of breast cancer cells with highly aneuploid (i.e. > 5 C) DNA content does not possess independent prognostic information in LN + breast cancer. An association remains to be tested in lymph node negative breast cancer.

[1]  P. Gimotty,et al.  A retrospective analysis of breast cancer based on outcome differences. , 1991, Human pathology.

[2]  I. Ellis,et al.  An observation of DNA ploidy, histological grade, and immunoreactivity for tumour‐related antigens in primary and metastatic breast carcinoma , 1989, The Journal of pathology.

[3]  J. Ploem,et al.  Use of DNA image cytometry in addition to flow cytometry for the study of patients with advanced ovarian cancer. , 1987, Cancer research.

[4]  Bartow Sa,et al.  DNA flow cytometry in solid tumors: practical aspects and clinical applications. , 1989 .

[5]  W. McGuire,et al.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.

[6]  G. Auer,et al.  Prognostic significance of dna measurements in 409 consecutive breast cancer patients , 1988, Cancer.

[7]  C. Cornelisse,et al.  DNA image cytometry on machine-selected breast cancer cells and a comparison between flow cytometry and scanning cytophotometry. , 1985, Cytometry.

[8]  A. Lee,et al.  Quantitative DNA analysis in breast carcinomas: a comparison between image analysis and flow cytometry. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[10]  H. Tanke,et al.  Preparation of monolayer smears from paraffin-embedded tissue for image cytometry. , 1985, Cytometry.

[11]  L. Skoog,et al.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content , 2005, Breast Cancer Research and Treatment.

[12]  R. Gray,et al.  Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial , 1990, Cancer.

[13]  S. Shackney,et al.  Model for the genetic evolution of human solid tumors. , 1989, Cancer research.

[14]  J H Lubin,et al.  Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.

[15]  J. Meyer,et al.  Regional heterogeneity in breast carcinoma: Thymidine labelling index, steroid hormone receptors, dna ploidy , 1991, International journal of cancer.

[16]  J. Ploem,et al.  Automated cell analysis for DNA studies of large cell populations using the LEYTAS image cytometry system. , 1989, Pathology, research and practice.

[17]  R. Gray,et al.  Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. S. Ploem,et al.  Image analysis combined with quantitative cytochemistry , 1986, Histochemistry.

[19]  L. Sleeper,et al.  Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N Breslow,et al.  Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. , 1986, Biometrics.

[21]  G. Auer,et al.  Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors. A retrospective study of 227 consecutive cases , 1988, Cancer.

[22]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[23]  L. Dressler,et al.  DNA flow cytometry in solid tumors: practical aspects and clinical applications. , 1989, Seminars in diagnostic pathology.